Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
UCB Biosciences

Organization & Developments: UCB

Parents

2022: UCB Reports Positive Pivotal for New Approach to Hidradenitis Suppurativa (Updated)
2024: Biogen, UCB report phase 3 lupus win, justifying risky bet on asset that failed earlier trial
2024: UCB's tau drug flunks phase 2 Alzheimer's trial days after Roche's exit from $120M bet
A global biopharma focused on severe diseases with operations in approximately 40 countries and global revenue of € 3.4 billion in 2012.
A team of approximately 7,500 employees and operations in more than 40 countries
Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development at our Research Triangle Park, North Carolina campus (UCB Biosciences, Inc.), and research supporting UCB’s pipeline in Cambridge, Massachusetts (UCB Research, Inc.).